Anocca Appoints Leading Strategic and Operational Global Drug Developer Sandra Bevan as Head of Clinical Development

Södertälje, Sweden, 9 November 2021 – Anocca AB, a leader in unlocking the potential of T cell immunotherapy to deliver transformative T cell receptor engineered T cell therapeutics (TCR-T), today announced it has appointed a new Head of Clinical Development, Sandra Bevan MSc.

Read the full release here.